ARTICLE | Emerging Company Profile
Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round
The Dutch and Israeli company plans to take pridopidine into pivotal studies for Huntington’s, ALS
June 4, 2020 1:38 AM UTC
Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively than approved therapies.
The biotech raised $62.5 million in a Forbion-led series A on Wednesday, which will fund a Phase III trial in Huntington’s disease and a Phase IIb platform trial in amyotrophic lateral sclerosis...
BCIQ Company Profiles
BCIQ Target Profiles